| Main Subject |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Outsourcing > Top 10 Selection Criteria for Outsourced Electronic Medical Billing Software as a Service (SaaS) |
|
Main Subject - Top 10 Selection Criteria for Outsourced Electronic Medical Billing Software as a Service (SaaS)
Software as a Service (SaaS) is the new generation of ASP model designed to reduce the exorbitant costs of specialized medical practice management software. SaaS model is available for all aspects of medical practice management, including scheduling, billing, and electronic medical records (EM According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product R), which are mission-critical for high quality clinical service, business operations, and regulatory compliance. SaaS model extends the advantages of Application Service Provider (ASP) model, which in turn evolves from the traditional Client-Server model. This article briefly defines key con ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in epts and outlines a set of guidelines for SaaS vendor selection. Client-Server (CS) Model CS model involves central servers for database and application logic and multiple client modules connected to the central servers via local area network. This architecture allows allocation of lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. significant application logic on the client computer. Applications architects considering CS model must weigh performance and security advantages against increased maintenance costs. CS benefits stem from local control of application logic and data. CS shortcomings too stem from localizing l here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe gic and data because local arrangement requires the user to take responsibility over application maintenance, including data security, redundancy, disaster recovery, upgrades, backups, etc. The medical practice utilizing CS model must develop in-house expertise and manage numerous services, in d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro luding
ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc /li>
Financially, CS models require the software user to make significant upfront investment in hardware and licensing and justify the business case using ROI-based arguments, which make little sense because of software and hardware innovation pace. Application Service Provider (AS easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi ) Model ASP model shields the medical practice from high cost of specialized software and data maintenance responsibilities but not from upfront investment in hardware and in software licenses. Early ASP applications were created from traditional CS applications by moving centralized dat nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically a and application servers to a third-party hosting service provider and allowing access to the application via HTML user interface as an afterthought. The third-party hosting service provider would take the responsibility for application maintenance and data protection. The medical practice u and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ing early ASP model manages two costs:
Software as a Service (SaaS) Model SaaS model extends ASP benefits from outsourcing ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi of system maintenance to simplified financial responsibilities. SaaS vendors eliminate the upfront costs to medical practice by making the upfront investment in hardware and licensing on behalf of all medical practices using the application. To make such a financial commitment, the hosting ve ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a ndor must develop thorough expertise in application maintenance and new feature development. Such a requirement became feasible with recent technology progress in terms of security (128-bit SSL encryption) and browser-based client performance along with AJAX coding methodology. The new genera dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ion technology now compensates for earlier CS model deficiencies and justifies network-native SaaS software development by design. Because of higher specialization, SaaS vendor is able to focus on client business requirements, resulting in more responsive service and higher client satisfaction cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin . SaaS Vendor Selection Medical practice in search of SaaS vendor must focus on the following topics:
tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen financial, practice workflow and personnel objectives? Have you considered integrated practice management functionality including patient scheduling, SOAP notes, and billing? t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tice workflow changes or available software functionality? ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust later? y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products gged using secure mechanism? . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de resolution? How is it tracked? elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip Disaster Recovery: How long would it take to recover from a disaster? Is a secondary data center available 24 x 7? tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Liberate Your Time by Developing Your Company Organization Chart Marketing, Lead Generation, and Research: A 3-in-1 Solution How Invoice Discounting Helps Your Business' Cash Flow
|